Teva may have some competition

Mylan a big maker of generics like Teva has teamed up with Natco an Indian Pharmaceutical, who makes a generic of Copaxone. They have been fighting with Teva in U.S. Courts over patent infringement for years.

PITTSBURGH, Sept. 14 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone®, a product indicated for the treatment of multiple sclerosis.

This will probably take awhile before a generic is available in the U.S., but at least Teva will no longer have a one of a kind MS drug.

Alex

[PastorDan]

I am a firm believer in the concept that competition in open markets is almost always a good thing, but remember, caveat emptor.

[Wobbly]

haha...I'm sorry, I don't seem to understand any of this...but that's OK..

it happens at times..

take care
wobbly
dx

[HVAC]

Another company is getting FDA approval for a generic of Copaxone which has been in production in India for two years. They will have to go through clinical trials in the U.S.

Basically if you need Glatiramer Acetate, Copaxone, another company will have a generic at a lower price.

Alex